Drugs / rAAV.sFLT-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01494805 | Dec 2011 → May 2017 | age-related macular degeneration, retinal vascular disorder | Lions Eye Institute, Perth, Western Australia | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2015-06-15 | Adverum Biotechnologies, Inc. | Results Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration adverum.com ↗
AVA-101 also showed an improvement on best corrected visual acuity (BCVA) compared with the control group and a positive trend in response rate (stable vision with few rescue injections). |
| 2015-05-14 | Adverum Biotechnologies, Inc. | Results Avalanche Biotechnologies Presents Three Posters at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting adverum.com ↗
Enrolled subjects are representative of the wet AMD population under current treatment with anti-VEGF therapy with variable visual acuity and prior treatment. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-06-15 | Adverum Biotechnologies, Inc. | Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration adverum.com ↗ |
| 2015-05-14 | Adverum Biotechnologies, Inc. | Avalanche Biotechnologies Presents Three Posters at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting adverum.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV.sFLT-1 | “Subretinal injection of rAAV.sFLT-1 was highly reproducible.” PMID 26431823 ↗ Sep 2015 |
| Modality | Gene therapy (AAV / viral vector) | “subretinal rAAV.sFLT-1 gene therapy” PMID 27865764 ↗ Nov 2016 |
| Route | Other | “delivered by subretinal injection” NCT01494805 ↗ |